Evidence map›Paper›PMID 40417125›Full record

ArticleFrontiers in neurology2025

AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis.

M Niiranen, P Bendel, J Koikkalainen, J Lötjönen, T Selander, E Solje, P Hartikainen, S Simula, R Vanninen, A M Portaankorva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M NiiranenDepartment of Neurology, Neuro Center, Kuopio University Hospital, Kuopio, Finland.
P BendelDepartment of Radiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
J KoikkalainenCombinostics Ltd., Tampere, Finland.
J LötjönenCombinostics Ltd., Tampere, Finland.
T SelanderScience Service Center, Kuopio University Hospital, Kuopio, Finland.
E SoljeDepartment of Neurology, Neuro Center, Kuopio University Hospital, Kuopio, Finland.
P HartikainenDepartment of Neurology, Neuro Center, Kuopio University Hospital, Kuopio, Finland.
S SimulaDepartment of Neurology, Mikkeli Central Hospital, Mikkeli, Finland.
R VanninenDepartment of Radiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
A M PortaankorvaClinical Neurosciences, University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The existence and definition of benign multiple sclerosis (MS) remain controversial, particularly given the discrepancy between clinical presentation and underlying imaging changes. In this study, we aimed to investigate the brain atrophy patterns related to benign relapsing-remitting MS (BRRMS), particularly regarding location and extent. Methods: We analyzed global and regional gray matter (GM) and white matter (WM) volumes, WM lesion load, corpus callosum index (CCI) and corpus callosum area (CCA) in well-defined benign relapsing-remitting MS patients (BRRMS, Results: Total brain tissue volume was significantly smaller in patients with BRRMS compared to HC ( Conclusions: Despite the overall reduced brain volume compared to HC, distinct cortical regions, especially within the limbic system (i.e., cingulate gyrus and entorhinal area) GM may be relatively well preserved, indicating a possible compensatory volume increase. Based on this study, the corpus callosum is a crucial structure in monitoring disease progression in BRRMS.

Indexed as

benign multiple sclerosisbrain atrophybrain volumetrycorpus callosum indexMRI

Identifiers

PMID40417125
PMCPMC12099013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.